Loading…
Health Plus Inc., a pharmaceutical drug manufacturer, violated Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, rendering its drug products adulterated. During a June-July 2021 inspection, the FDA identified that the company failed to adequately inspect, investigate, and test returned drug products before redistributing them, relying solely on visual examination rather than proper testing to confirm safety, identity, strength, quality, and purity. Additionally, the firm improperly combined returned capsules from multiple lots into new batches with new lot numbers without ensuring uniform character and quality across the consolidated products.